Alterations of immune status induced by the sympathetic nervous system: immunomodulatory effects of DMPP alone and in combination with morphine.
The aim of the present study was to explore the involvement of the sympathetic nervous system (SNS) in the immunomodulatory effects of morphine in Lewis rats and to assess the effects of alterations in SNS activity on immune status. In the first experiment, sympathetic tone was elevated by administering the ganglionic stimulant 1,1-dimethyl-4-phenylpiperazinium (DMPP) in doses of 0, 0.01, 0.1, and 1.0 mg/kg, sc, 5 min before the sc administration of 15 mg/kg morphine or saline. Animals were sacrificed 1 h after the morphine injection and multiple in vitro immune assays were then conducted. Although DMPP did not significantly enhance morphine's suppressive effects in the spleen and blood mitogen stimulation assays or the splenic natural killer (NK) cell assay, DMPP alone produced effects on immune status in saline-treated animals. Therefore, a second experiment was conducted to examine the immunomodulatory effects of increasing peripheral sympathetic outflow in greater detail. Animals were administered a wider dose range of DMPP (0, 0.005, 0.05, 0.5, and 5.0 mg/kg, sc) 30 min prior to sacrifice and an expanded repertoire of immune assays was conducted. DMPP dose-dependently suppressed the mitogenic responsiveness of splenic T lymphocytes, splenic NK cell activity, and interleukin-2 (IL-2) and gamma-interferon production by stimulated splenocytes. DMPP did not alter the total number of splenic leukocytes or the proliferative response of splenic B lymphocytes. In the mesenteric lymph nodes, DMPP had no effect on mitogenic responsiveness, the production of IL-2 or the total number of leukocytes. In the blood, however, DMPP increased mitogenic responsiveness at intermediate doses and decreased proliferation at higher doses. DMPP also dose-dependently decreased the number of blood leukocytes/ml. Taken together, these results indicate that increasing peripheral sympathetic outflow results in profound effects on immune status that depend upon the degree to which SNS activity is altered, the compartment of the immune system, and the lymphocyte subtype.
Fecho
K
K
Curriculum in Neurobiology, University of North Carolina at Chapel Hill 27599-3270.
Maslonek
K A
KA
Dykstra
L A
LA
Lysle
D T
DT
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D004246:Dimethylphenylpiperazinium Iodide / Q000008:administration & dosage / Q000494:pharmacology*; D004347:Drug Interactions; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007371:Interferon-gamma / Q000096:biosynthesis; D007376:Interleukin-2 / Q000096:biosynthesis; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D009020:Morphine / Q000494:pharmacology*; D015213:Neuroimmunomodulation / Q000187:drug effects*; D051381:Rats; D011917:Rats, Inbred Lew / Q000276:immunology / Q000502:physiology; D013154:Spleen / Q000276:immunology; D017779:Sympathetic Fibers, Postganglionic / Q000187:drug effects*; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology*
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D004246:Dimethylphenylpiperazinium Iodide; D009020:Morphine; D007371:Interferon-gamma